Welcome to our dedicated page for Barrick Mining Corporation news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining Corporation stock.
The Barrick Mining Corporation (NYSE: B, TSX: ABX) news page on Stock Titan provides a focused view of company announcements and market-facing disclosures for one of the world’s largest gold miners. Barrick’s news flow reflects its role as a major producer of gold and copper, with operations and projects across the Americas, Africa, the Middle East, and Asia.
Investors following B stock can use this page to track key corporate updates that shape the company’s outlook. These include notices about upcoming earnings releases and webcasts, such as the announcement that Barrick will report its full year and fourth quarter 2025 results on February 5, 2026, with a live webcast and analyst question-and-answer session. Such events offer insight into production performance, costs, project progress, and capital allocation decisions.
Alongside earnings-related news, Barrick’s regulatory communications often appear in the form of press releases furnished with its Form 6-K filings. These may cover quarterly results, comparative unaudited financial statements prepared in accordance with International Financial Reporting Standards, management’s discussion and analysis, and capital management actions such as share buyback programs.
By reviewing the Barrick Mining Corporation news feed, readers can monitor how the company reports on its gold and copper production profile, reserve base, and key projects like the Lumwana expansion and the Reko Diq copper and gold development. Bookmark this page to quickly access the latest Barrick announcements, scheduled results dates, and other official disclosures that inform analysis of the B stock.
Hexagon AB has announced that its nomination committee proposes Björn Rosengren as new Vice Chairman of the Board at the Annual General Meeting on May 5, 2025. This move is part of succession planning as current Chairman Ola Rollén has indicated his intention to step down at the 2026 AGM after 26 years on the board. Rosengren, who previously served as CEO of ABB and Sandvik AB, will be positioned to take over the chairmanship. The announcement also notes that board member Brett Watson will not seek re-election in 2025.
Hexagon is a global leader in precision technologies with approximately 24,500 employees across 50 countries and net sales of about 5.4bn EUR.
SimScale and Hexagon's Manufacturing Intelligence division have announced a strategic partnership to deliver advanced structural analysis capabilities through a cloud-native platform. The collaboration integrates Hexagon's Marc nonlinear finite element solver into SimScale's browser-based platform as a Software-as-a-Service (SaaS) solution. This partnership aims to democratize access to advanced simulation tools, enabling engineering teams of all sizes to perform complex structural analyses without requiring extensive technical expertise or specialized IT infrastructure. The platform features live in-product support and has been ranked first in user satisfaction in the Simulation & CAE Software category by G2.
Eisai has launched Leqembi® in South Korea following its approval in May 2024 for treating early Alzheimer's disease (AD). The drug targets approximately 900,000 dementia patients in South Korea, where about 70% have Alzheimer's dementia. Leqembi, developed through collaboration between BioArctic and Eisai, is the first approved treatment that reduces disease progression by targeting amyloid-beta aggregates. The initial launch will be in the private market, with BioArctic retaining rights for joint commercialization in the Nordic region pending European approval.
Hexagon has announced the acquisition of indurad, a German-based leader in radar and Real-Time Location Systems technologies, along with its autonomous haulage subsidiary, xtonomy. The acquisition aims to enhance mine safety through advanced radar-based collision avoidance systems and increase productivity via real-time ore tracking. indurad reported revenues of approximately 19 MEUR in 2023 and has 140 employees globally. The transaction is expected to close in late November, with indurad being consolidated into Hexagon's Autonomous Solutions division. While initially below Hexagon Group levels, profitability is expected to improve as synergies are realized.
BioArctic AB announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for lecanemab as an Alzheimer's disease treatment in the EU. The recommendation applies to adult patients with early Alzheimer's who are apolipoprotein E ε4 heterozygotes or non-carriers. This follows a re-examination of CHMP's earlier negative recommendation, with European Commission's decision expected within 67 days. Lecanemab is already approved in multiple countries including the US, Japan, and China. BioArctic holds Nordic region commercialization rights, while partner Eisai handles development and commercialization elsewhere.
BioArctic AB announced that its partner Eisai has revised down its revenue forecast for Leqembi for fiscal year 2024 (April 2024-March 2025) to JPY 42.5 billion from JPY 56.5 billion previously announced in May. This adjustment would generate approximately SEK 300M in royalty for BioArctic. First-half FY2024 Leqembi sales reached JPY 16.3 billion, resulting in SEK 112.4M royalty to BioArctic. Eisai leads Leqembi's development and regulatory submissions globally, with Biogen co-commercializing the product. BioArctic maintains Nordic region commercialization rights, pending European approval.
BioArctic AB has unveiled its proprietary BrainTransporter (BT) platform at the PEGS conference in Barcelona. The technology demonstrates up to 70-fold higher penetration of antibodies across the blood-brain barrier using Transferrin Receptor-mediated transport, without negative effects on hematological safety. The platform shows rapid, broad, and deep distribution of amyloid-beta antibodies across the brain in preclinical models. In April 2024, BioArctic and Eisai entered a research evaluation agreement for BAN2802, combining BT technology with an Alzheimer drug candidate.
BioArctic AB (NASDAQ STOCKHOLM: BIOA B) has announced it will release its Q3 2024 report for July-September on November 14, 2024, at 08:00 CET. The company will host an audiocast with teleconference in English at 09:30 CET where CEO Gunilla Osswald and CFO Anders Martin-Löf will present the quarterly results and conduct a Q&A session. Participants can join via webcast or teleconference, with both options requiring pre-registration. The presentation will be available on-demand afterward on BioArctic's corporate website.
Crawford & Company (NYSE: CRD-A and CRD-B) announced that its Board of Directors has declared a quarterly dividend of $0.07 per share for both Class A and Class B Common Stock. The dividend will be paid on December 6, 2024, to shareholders of record as of the close of business on November 19, 2024. The declaration was made during the company's regular quarterly board meeting on October 31, 2024.
BioArctic AB's partner Eisai has completed a rolling Biologics License Application (BLA) submission to the FDA for Leqembi subcutaneous autoinjector for weekly maintenance dosing in early Alzheimer's disease treatment. The autoinjector would allow for 15-second home administration after completing the initial IV phase. The application is based on Clarity AD open-label extension study data. Leqembi is currently approved in multiple countries including the US, Japan, and China, with pending applications in 10 other regions. The FDA is also reviewing a separate application for monthly IV maintenance dosing with a PDUFA date of January 25, 2025.